-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Imago BioSciences (NASDAQ:IMGO) Shares Gap Up to $14.88
Imago BioSciences (NASDAQ:IMGO) Shares Gap Up to $14.88
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares gapped up before the market opened on Wednesday . The stock had previously closed at $14.88, but opened at $15.30. Imago BioSciences shares last traded at $15.30, with a volume of 100 shares traded.
Analysts Set New Price Targets
Separately, HC Wainwright lowered their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Stock Up 1.9 %
The business's 50 day moving average is $16.32 and its 200-day moving average is $17.09. The firm has a market capitalization of $565.85 million, a P/E ratio of -9.42 and a beta of 2.48.
Insider Activity at Imago BioSciences
In related news, insider Jennifer Peppe sold 5,598 shares of Imago BioSciences stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $19.41, for a total value of $108,657.18. Following the transaction, the insider now directly owns 148,809 shares of the company's stock, valued at $2,888,382.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 8,168 shares of company stock valued at $155,402 over the last three months. 14.90% of the stock is owned by insiders.Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in IMGO. Northern Trust Corp increased its stake in Imago BioSciences by 25.0% in the fourth quarter. Northern Trust Corp now owns 107,122 shares of the company's stock valued at $2,541,000 after acquiring an additional 21,413 shares during the last quarter. Swiss National Bank acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $612,000. Ensign Peak Advisors Inc acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $593,000. Virtus ETF Advisers LLC acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $215,000. Finally, Citadel Advisors LLC boosted its position in Imago BioSciences by 20.1% in the fourth quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after buying an additional 410,487 shares in the last quarter. 99.50% of the stock is owned by institutional investors.
Imago BioSciences Company Profile
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Read More
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares gapped up before the market opened on Wednesday . The stock had previously closed at $14.88, but opened at $15.30. Imago BioSciences shares last traded at $15.30, with a volume of 100 shares traded.
意马生物科学公司(纳斯达克代码：IMGO-GET Rating)的股票在周三开盘前大幅上涨。该股此前收盘报14.88美元，开盘报15.30美元。Imago BioSciences的股票尾盘报15.30美元，成交量为100股。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, HC Wainwright lowered their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
另外，在8月16日(星期二)的一份报告中，HC Wainwright将Imago BioSciences的目标价从36.00美元下调至35.00美元，并对该股设定了买入评级。
Imago BioSciences Stock Up 1.9 %
Imago BioSciences股价上涨1.9%
The business's 50 day moving average is $16.32 and its 200-day moving average is $17.09. The firm has a market capitalization of $565.85 million, a P/E ratio of -9.42 and a beta of 2.48.
该业务的50日移动均线切入位在16.32美元，200日移动均线切入位在17.09美元。该公司的市值为5.6585亿美元，市盈率为-9.42，贝塔系数为2.48。
Insider Activity at Imago BioSciences
Imago BioSciences的内部活动
Institutional Inflows and Outflows
机构资金流入和流出
A number of hedge funds have recently added to or reduced their stakes in IMGO. Northern Trust Corp increased its stake in Imago BioSciences by 25.0% in the fourth quarter. Northern Trust Corp now owns 107,122 shares of the company's stock valued at $2,541,000 after acquiring an additional 21,413 shares during the last quarter. Swiss National Bank acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $612,000. Ensign Peak Advisors Inc acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $593,000. Virtus ETF Advisers LLC acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $215,000. Finally, Citadel Advisors LLC boosted its position in Imago BioSciences by 20.1% in the fourth quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after buying an additional 410,487 shares in the last quarter. 99.50% of the stock is owned by institutional investors.
一些对冲基金最近增持或减持了IMGO的股份。北方信托公司在第四季度增持了Imago BioSciences 25.0%的股份。Northern Trust Corp目前持有107,122股该公司股票，价值2,541,000美元，此前该公司在上一季度增持了21,413股。瑞士国家银行在第四季度收购了Imago BioSciences的新股份，价值约为61.2万美元。Ensign Peak Advisors Inc.在第四季度收购了Imago BioSciences的新股份，价值约593,000美元。Virtus ETF Advisers LLC在第四季度收购了Imago BioSciences的新股份，价值约21.5万美元。最后，Citadel Advisors LLC在第四季度将其在Imago BioSciences的地位提高了20.1%。Citadel Advisors LLC现在拥有2,452,926股该公司股票，价值57,271,000美元，上个季度又购买了410,487股。99.50%的股票由机构投资者持有。
Imago BioSciences Company Profile
Imago BioSciences公司简介
(Get Rating)
(获取评级)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
临床阶段生物制药公司Imago BioSciences，Inc.发现和开发了针对赖氨酸特异性脱甲基酶1(LSD1)的小分子产品候选产品，LSD1是一种用于生产骨髓中血细胞的酶。它的主要候选产品是Bomedemstat，正在进行第二阶段临床试验，用于治疗骨髓增生性肿瘤和慢性骨髓癌，如骨髓纤维化、原发性血小板增多症和真性红细胞增多症。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- 免费获取StockNews.com关于Imago BioSciences(IMGO)的研究报告
- 石油和天然气股票：投资可再生能源的安全途径
- 这些绿色能源公司适合你的投资组合吗？
- 希捷科技的宿醉何时才能结束？
- 安相能源有足够的动力继续提高动力吗？
- 独一无二的氢燃料电池库存
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Imago BioSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧